Therapy of primary sclerosing cholangitis - Today and tomorrow

Digestive Diseases

Volumn 33, Issue , 2015, Pages 149-163

  Halilbasic, Emina ^a   Fuchs, Claudia ^a   Hofer, Harald ^a   Paumgartner, Gustav ^a   Trauner, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bile acid signaling; FXR; Norursodeoxycholic acid; Obeticholic acid; TGR5; Ursodeoxycholic acid

Indexed keywords

FARNESOID X RECEPTOR; LITHOCHOLIC ACID; NORUCHOLIC ACID; OBETICHOLIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PREBIOTIC AGENT; PROBIOTIC AGENT; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; SIMTUZUMAB; URSODEOXYCHOLIC ACID; VEDOLIZUMAB; VITAMIN D RECEPTOR; 24-NORURSODEOXYCHOLIC ACID; CELL RECEPTOR; CHOLAGOGUE; FARNESOID X-ACTIVATED RECEPTOR;

ARTICLE; BILE DUCT CARCINOMA; CARCINOGENESIS; CHOLANGIOCYTE; CHRONIC LIVER DISEASE; COLONOSCOPY; COLORECTAL CANCER; DYSPLASIA; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FECES MICROFLORA; HUMAN; INFLAMMATORY BOWEL DISEASE; LIVER CANCER; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; LUNG FIBROSIS; LYMPHOCYTE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; SCHISTOSOMIASIS; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; WILSON DISEASE; ANALOGS AND DERIVATIVES; CHOLANGITIS, SCLEROSING; INTESTINE FLORA;

CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; GASTROINTESTINAL MICROBIOME; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; URSODEOXYCHOLIC ACID;

EID: 84977459436     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000440827     Document Type: Article

References (182)

1. Trauner M, Halilbasic E, Baghdasaryan A, Moustafa T, Krones E, Fickert P, Hofer H, Penner E: Primary sclerosing cholangitis: new approaches to diagnosis, surveillance and treatment. Dig Dis 2012;30(suppl 1):39-47.
2. Björnsson E, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman RW, Boberg KM, Angulo P: The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008;134:975-980.
3. Razumilava N, Gores GJ, Lindor KD: Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 2011;54:1842-1852.
4. Williamson KD, Chapman RW: Primary sclerosing cholangitis. Dig Dis 2014;32:438-445.
5. Rizvi S, Eaton JE, Gores GJ: Primary sclerosing cholangitis as a pre-malignant biliary tract disease: surveillance and management. Clin Gastroenterol Hepatol 2015;pii:S1542-3565(15)00770-3.
6. Alswat K, Al-Harthy N, Mazrani W, Alshumrani G, Jhaveri K, Hirschfield GM: The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice. Am J Gastroenterol 2012;107:56-63.
7. Beuers U, Maillette de Buy Wenniger LJ, Doorenspleet M, Hubers L, Verheij J, van Gulik T, van de Graaf SF, de Vries N: IgG4-associated cholangitis. Dig Dis 2014;32:605-608.
8. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Lööf L, Danielsson A, Hultcrantz R, Lindgren S, Prytz H, Sandberg-Gertzén H, Almer S, Granath F, Broomé U: Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-327.
9. Broomé U, Olsson R, Lööf L, Bodemar G, Hultcrantz R, Danielsson A, Prytz H, Sand-berg-Gertzén H, Wallerstedt S, Lindberg G: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610-615.
10. Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, van Nieuwkerk KM, Drenth JP, Witteman BJ, Tuynman HA, Naber AH, Kingma PJ, van Buuren HR, van Hoek B, Vleggaar FP, van Geloven N, Beuers U, Ponsioen CY; EpiPSCPBC Study Group: Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013;58:2045-2055.
11. Said K, Glaumann H, Bergquist A: Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol 2008;48:598-605.
12. Ananthakrishnan AN, Cagan A, Gainer VS, Cheng SC, Cai T, Szolovits P, Shaw SY, Churchill S, Karlson EW, Murphy SN, Kohane I, Liao KP: Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. J Crohns Colitis 2014;8:956-963.
13. Harnois DM, Gores GJ, Ludwig J, Steers JL, LaRusso NF, Wiesner RH: Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J Hepatol 1997;27:512-516.
14. de Valle MB, Björnsson E, Lindkvist B: Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver Int 2012;32:441-448.
15. Zenouzi R, Weismüller TJ, Hübener P, Schulze K, Bubenheim M, Pannicke N, Weiler-Normann C, Lenzen H, Manns MP, Lohse AW, Schramm C: Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis. Clin Gastroenterol Hepatol 2014;12:1733-1738.
16. Ravikumar R, Tsochatzis E, Jose S, Allison M, Athale A, Creamer F, Gunson B, Iyer V, Madanur M, Manas D, Monaco A, Mirza D, Owen N, Roberts K, Sen G, Srinivasan P, Wigmore S, Fusai G, Fernando B, Burroughs A: Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol 2015;pii:S0168-8278(15)00467-5.
17. Fosby B, Karlsen TH, Melum E: Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol 2012;18:1-15.
18. Barnabas A, Chapman RW: Primary sclerosing cholangitis: is any treatment worthwhile? Curr Gastroenterol Rep 2012;14:17-24.
19. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F: High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808-814.
20. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, Bell H, Gangsøy-Kristiansen M, Matre J, Rydning A, Wikman O, Danielsson A, Sandberg-Gertzén H, Ung KA, Eriksson A, Lööf L, Prytz H, Marschall HU, Broomé U: High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129: 1464-1472.
21. Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK: Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther 2011;34:901-910.
22. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-267.
23. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ; American Association for the Study of Liver Diseases: Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-678.
24. Tabibian JH, Lindor KD: Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?). Hepatology 2014;60:785-788.
25. Wunsch E, Trottier J, Milkiewicz M, Raszeja-Wyszomirska J, Hirschfield GM, Barbier O, Milkiewicz P: Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology 2014;60:931-940.
26. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889-893.
27. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA: Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95.
28. Wolf JM, Rybicki LA, Lashner BA: The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2005;22:783-788.
29. Navaneethan U, Kochhar G, Venkatesh PG, Lewis B, Lashner BA, Remzi FH, Shen B, Kiran RP: Duration and severity of primary sclerosing cholangitis is not associated with risk of neoplastic changes in the colon in patients with ulcerative colitis. Gastrointest Endosc 2012;75:1045-1054.e1.
30. Lindström L, Boberg KM, Wikman O, Friis-Liby I, Hultcrantz R, Prytz H, Sandberg-Gertzén H, Sangfelt P, Rydning A, Folvik G, Gangsøy-Kristiansen M, Danielsson A, Bergquist A: High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther 2012;35:451-457.
31. Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Lindor KD: High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011;106: 1638-1645.
32. Jørgensen KK, Lindström L, Cvancarova M, Castedal M, Friman S, Schrumpf E, Foss A, Isoniemi H, Nordin A, Holte K, Rasmussen A, Bergquist A, Vatn MH, Boberg KM: Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study. Scand J Gastroenterol 2012;47:1021-1029.
33. Singh S, Edakkanambeth Varayil J, Loftus EV Jr, Talwalkar JA: Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis. Liver Transpl 2013;19: 1361-1369.
34. Ochsenkühn T, Marsteller I, Hay U, Diebold J, Paumgartner G, Göke B, Sackmann M: Does ursodeoxycholic acid change the proliferation of the colorectal mucosa? A randomized, placebo-controlled study. Digestion 2003;68:209-216.
35. Rudolph G, Kloeters-Plachky P, Rost D, Stiehl A: The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol 2007;19: 487-491.
36. Brandsaeter B, Isoniemi H, Broomé U, Olausson M, Bäckman L, Hansen B, Schrumpf E, Oksanen A, Ericzon BG, Höckerstedt K, Mäkisalo H, Kirkegaard P, Friman S, Bjøro K: Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004;40: 815-822.
37. Chapman MH, Webster GJ, Bannoo S, Johnson GJ, Wittmann J, Pereira SP: Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. Eur J Gastroenterol Hepatol 2012;24:1051-1058.
38. Björnsson E, Lindqvist-Ottosson J, Asztely M, Olsson R: Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 2004;99:502-508.
39. Craig DA, MacCarty RL, Wiesner RH, Grambsch PM, LaRusso NF: Primary sclerosing cholangitis: value of cholangiography in determining the prognosis. AJR Am J Roentgenol 1991;157:959-964.
40. Olsson RG, Asztély MS: Prognostic value of cholangiography in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 1995;7: 251-254.
41. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, Rajaram R, Rauws EA, Mulder CJ, Reitsma JB, Heisterkamp SH, Tytgat GN: Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002;51:562-566.
42. Stiehl A, Rudolph G, Sauer P, Benz C, Stremmel W, Walker S, Theilmann L: Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol 1997;26:560-566.
43. Baluyut AR, Sherman S, Lehman GA, Hoen H, Chalasani N: Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001;53:308-312.
44. Stiehl A, Rudolph G, Klöters-Plachky P, Sauer P, Walker S: Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002;36:151-156.
45. Johnson GK, Geenen JE, Venu RP, Hogan WJ: Endoscopic treatment of biliary duct strictures in sclerosing cholangitis: follow-up assessment of a new therapeutic approach. Gastrointest Endosc 1987;33:9-12.
46. Johnson GK, Geenen JE, Venu RP, Schmalz MJ, Hogan WJ: Endoscopic treatment of biliary tract strictures in sclerosing cholangitis: a larger series and recommendations for treatment. Gastrointest Endosc 1991;37:38-43.
47. Gaing AA, Geders JM, Cohen SA, Siegel JH: Endoscopic management of primary sclerosing cholangitis: review, and report of an open series. Am J Gastroenterol 1993;88:2000-2008.
48. Ahrendt SA, Pitt HA, Kalloo AN, Venbrux AC, Klein AS, Herlong HF, Coleman J, Lillemoe KD, Cameron JL: Primary sclerosing cholangitis: resect, dilate, or transplant? Ann Surg 1998;227:412-423.
49. Wagner S, Gebel M, Meier P, Trautwein C, Bleck J, Nashan B, Manns MP: Endoscopic management of biliary tract strictures in primary sclerosing cholangitis. Endoscopy 1996; 28:546-551.
50. Lee JG, Schutz SM, England RE, Leung JW, Cotton PB: Endoscopic therapy of sclerosing cholangitis. Hepatology 1995;21:661-667.
51. Ponsioen CY, Lam K, van Milligen de Wit AW, Huibregtse K, Tytgat GN: Four years' experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol 1999;94:2403-2407.
52. van Milligen de Wit AW, Rauws EA, van Bracht J, Mulder CJ, Jones EA, Tytgat GN, Huibregtse K: Lack of complications following short-term stent therapy for extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 1997;46:344-347.
53. Kaya M, Petersen BT, Angulo P, Baron TH, Andrews JC, Gostout CJ, Lindor KD: Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1059-1066.
54. de Vries AB, Janse M, Blokzijl H, Weersma RK: Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol 2015;21:1956-1971.
55. Cesaro C, Tiso A, Del Prete A, Cariello R, Tuccillo C, Cotticelli G, Del Vecchio Blanco C, Loguercio C: Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis 2011;43:431-438.
56. Welcker K, Martin A, Kölle P, Siebeck M, Gross M: Increased intestinal permeability in patients with inflammatory bowel disease. Eur J Med Res 2004;9:456-460.
57. Eksteen B, Mora JR, Haughton EL, Henderson NC, Lee-Turner L, Villablanca EJ, Curbishley SM, Aspinall AI, von Andrian UH, Adams DH: Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells. Gastroenterology 2009;137:320-329.
58. Sokol H, Cosnes J, Chazouilleres O, Beaugerie L, Tiret E, Poupon R, Seksik P: Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol 2008;14:3497-3503.
59. Florin TH, Pandeya N, Radford-Smith GL: Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases. Gut 2004;53:973-979.
60. Sano H, Nakazawa T, Ando T, Hayashi K, Naitoh I, Okumura F, Miyabe K, Yoshida M, Takahashi S, Ohara H, Joh T: Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci 2011;18:154-161.
61. Loftus EV Jr, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, Jewell DA, Sandborn WJ: PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005;54:91-96.
62. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO: Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002;56: 48-54.
63. Lepistö A, Kivistö S, Kivisaari L, Arola J, Järvinen HJ: Primary sclerosing cholangitis: outcome of patients undergoing restorative proctocolecetomy for ulcerative colitis. Int J Colorectal Dis 2009;24:1169-1174.
64. Lepistö A, Kärkkäinen P, Järvinen HJ: Prevalence of primary sclerosing cholangitis in ulcerative colitis patients undergoing proctocolectomy and ileal pouch-anal anastomosis. Inflamm Bowel Dis 2008;14:775-779.
65. Singh S, Loftus EV Jr, Talwalkar JA: Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Am J Gastroenterol 2013;108:1417-1425.
66. Vera A, Moledina S, Gunson B, Hubscher S, Mirza D, Olliff S, Neuberger J: Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002;360:1943-1944.
67. Alabraba E, Nightingale P, Gunson B, Hubscher S, Olliff S, Mirza D, Neuberger J: A reevaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009;15:330-340.
68. Papatheodoridis GV, Hamilton M, Mistry PK, Davidson B, Rolles K, Burroughs AK: Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998;43:639-644.
69. Gelley F, Miheller P, Péter A, Telkes G, Nemes B: Activity of ulcerative colitis before and after liver transplantation in primary sclerosing cholangitis: the Hungarian experience. Transplant Proc 2012;44:2164-2165.
70. Jørgensen KK, Lindström L, Cvancarova M, Karlsen TH, Castedal M, Friman S, Schrumpf E, Foss A, Isoniemi H, Nordin A, Holte K, Rasmussen A, Bergquist A, Vatn MH, Boberg KM: Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11: 517-523.
71. Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F, Häuser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay JO; European Crohn's and Colitis Organisation: Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013;7:1-33.
72. Williamson KD, Chapman RW: Primary sclerosing cholangitis: a clinical update. Br Med Bull 2015;114:53-64.
73. Trauner M, Halilbasic E, Kazemi-Shirazi L, Kienbacher C, Staufer K, Traussnigg S, Hofer H: Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies. Dig Dis 2014;32:631-636.
74. Trauner M, Halilbasic E, Claudel T, Steinacher D, Fuchs C, Moustafa T, Pollheimer M, Krones E, Kienbacher C, Traussnigg S, Kazemi-Shirazi L, Munda P, Hofer H, Fickert P, Paumgartner G: Potential of nor-ursodeoxycholic acid in cholestatic and metabolic disorders. Dig Dis 2015;33:433-439.
75. Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M: 24-norursodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006;130: 465-481.
76. Moustafa T, Fickert P, Magnes C, Guelly C, Thueringer A, Frank S, Kratky D, Sattler W, Reicher H, Sinner F, Gumhold J, Silbert D, Fauler G, Höfler G, Lass A, Zechner R, Trauner M: Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology 2012;142:140-151. e12.
77. Halilbasic E, Claudel T, Bachhofner N, Kapusta C, Trauner M: Norursodeoxycholic acid modulates LPS-induced inflammatory response by interfering with NFkB signaling pathway. J Hepatol 2012;56:S140.
78. Liaskou E, Karikoski M, Reynolds GM, Lalor PF, Weston CJ, Pullen N, Salmi M, Jalkanen S, Adams DH: Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity. Hepatology 2011;53: 661-672.
79. Erle DJ, Briskin MJ, Butcher EC, Garcia-Par-do A, Lazarovits AI, Tidswell M: Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J Immunol 1994;153:517-528.
80. Hillan KJ, Hagler KE, MacSween RN, Ryan AM, Renz ME, Chiu HH, Ferrier RK, Bird GL, Dhillon AP, Ferrell LD, Fong S: Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease. Liver 1999;19: 509-518.
81. Ala A, Brown D, Khan K, Standish R, Odin JA, Fiel MI, Schiano TD, Hillan KJ, Rahman SA, Hodgson HJ, Dhillon AP: Mucosal addressin cell adhesion molecule (MAdCAM-1) expression is upregulated in the cirrhotic liver and immunolocalises to the peribiliary plexus and lymphoid aggregates. Dig Dis Sci 2013;58: 2528-2541.
82. Grant AJ, Lalor PF, Hübscher SG, Briskin M, Adams DH: MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology 2001; 33: 1065-1072.
83. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group: Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-721.
84. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group: Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
85. Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S: Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014;147: 618-627.e3.
86. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA: Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2:217-225.
87. Modica S, Petruzzelli M, Bellafante E, Murzilli S, Salvatore L, Celli N, Di Tullio G, Palasciano G, Moustafa T, Halilbasic E, Trauner M, Moschetta A: Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 2011;142:355-365.e1-e4.
88. Modica S, Murzilli S, Salvatore L, Schmidt DR, Moschetta A: Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res 2008;68:9589-9594.
89. Moon HJ, Finney J, Ronnebaum T, Mure M: Human lysyl oxidase-like 2. Bioorg Chem 2014;57:231-241.
90. Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, Mikels A, Vaysberg M, Ghermazien H, Wai C, Garcia CA, Velayo AC, Jorgensen B, Biermann D, Tsai D, Green J, Zaffryar-Eilot S, Holzer A, Ogg S, Thai D, Neufeld G, Van Vlasselaer P, Smith V: Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010;16:1009-1017.
91. Nakken KE, Nygård S, Haaland T, Berge KE, Arnkvaern K, Ødegaard A, Labori KJ, Raeder MG: Multiple inflammatory-, tissue remodel-ling- and fibrosis genes are differentially transcribed in the livers of Abcb4 (-/-) mice harbouring chronic cholangitis. Scand J Gastroenterol 2007;42:1245-1255.
92. Vadasz Z, Kessler O, Akiri G, Gengrinovitch S, Kagan HM, Baruch Y, Izhak OB, Neufeld G: Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. J Hepatol 2005;43:499-507.
93. Pollheimer MJ, Bowlus C, Lackner C, Karlsen TH, Hov JR, Lyman S, Adamkewicz J, Mikels-Vigdal A, Marshall D, Smith V, Trauner M, Fickert P: Lysyl oxidase-like 2 (LOXL2) protein is induced in human cholestatic liver disease and in animal models of cholangiopathies. J Hepatol 2013;58:S281-S282.
94. Xu J, Li D, Li X, Liu Z, Li T, Jiang P, He Q, Tian F, Gao Y, Wang D, Wang S: 67 laminin receptor promotes the malignant potential of tumour cells up-regulating lysyl oxidase-like 2 expression in cholangiocarcinoma. Dig Liver Dis 2014;46:750-757.
95. Wiel C, Augert A, Vincent DF, Gitenay D, Vindrieux D, Le Calvé B, Arfi V, Lallet-Daher H, Reynaud C, Treilleux I, Bartholin L, Lelievre E, Bernard D: Lysyl oxidase activity regulates oncogenic stress response and tumorigenesis. Cell Death Dis 2013;4: e855.
96. Cohen BI, Hofmann AF, Mosbach EH, Stenger RJ, Rothschild MA, Hagey LR, Yoon YB: Differing effects of nor-ursodeoxycholic or ursodeoxycholic acid on hepatic histology and bile acid metabolism in the rabbit. Gastroenterology 1986;91:189-197.
97. Halilbasic E, Fiorotto R, Fickert P, Marschall HU, Moustafa T, Spirli C, Fuchsbichler A, Gumhold J, Silbert D, Zatloukal K, Langner C, Maitra U, Denk H, Hofmann AF, Strazzabosco M, Trauner M: Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology 2009;49: 1972-1981.
98. Yoon YB, Hagey LR, Hofmann AF, Gurantz D, Michelotti EL, Steinbach JH: Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ur-sodeoxycholate in rodents. Gastroenterology 1986;90:837-852.
99. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, Marschall HU, Tsybrovskyy O, Zatloukal K, Denk H, Trauner M: Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002;123: 1238-1251.
100. Fickert P, Pollheimer MJ, Silbert D, Moustafa T, Halilbasic E, Krones E, Durchschein F, Thüringer A, Zollner G, Denk H, Trauner M: Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. J Hepatol 2013;58:1201-1208.
101. Beraza N, Ofner-Ziegenfuss L, Ehedego H, Boekschoten M, Bischoff SC, Mueller M, Trauner M, Trautwein C: Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. Gut 2011;60: 387-396.
102. Sombetzki M, Fuchs CD, Fickert P, Österreicher CH, Mueller M, Claudel T, Loebermann M, Engelmann R, Langner C, Sahin E, Schwinge D, Guenther ND, Schramm C, Mueller-Hilke B, Reisinger EC, Trauner M: 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. J Hepatol 2015;62:871-878.
103. Beuers U, Kullak-Ublick GA, Pusl T, Rauws ER, Rust C: Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators? Clin Rev Allergy Immunol 2009;36: 52-61.
104. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS: Bile acids and the gut microbiome. Curr Opin Gastroenterol 2014;30:332-338.
105. Modica S, Moschetta A: Nuclear bile acid receptor FXR as pharmacological target: are we there yet? FEBS Lett 2006;580:5492-5499.
106. Trauner M, Baghdasaryan A, Claudel T, Fickert P, Halilbasic E, Moustafa T, Zollner G: Targeting nuclear bile acid receptors for liver disease. Dig Dis 2011;29:98-102.
107. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K: Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008;7:678-693.
108. Gnerre C, Blättler S, Kaufmann MR, Looser R, Meyer UA: Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 2004;14:635-645.
109. Song CS, Echchgadda I, Baek BS, Ahn SC, Oh T, Roy AK, Chatterjee B: Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor. J Biol Chem 2001;276:42549-42556.
110. Barbier O, Torra IP, Sirvent A, Claudel T, Blanquart C, Duran-Sandoval D, Kuipers F, Kosykh V, Fruchart JC, Staels B: FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 2003; 124:1926-1940.
111. Chignard N, Mergey M, Barbu V, Finzi L, Tiret E, Paul A, Housset C: VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium. Hepatology 2005;42:549-557.
112. Gadaleta RM, Cariello M, Sabbà C, Moschetta A: Tissue-specific actions of FXR in metabolism and cancer. Biochim Biophys Acta 2015;1851:30-39.
113. Abel U, Schlüter T, Schulz A, Hambruch E, Steeneck C, Hornberger M, Hoffmann T, Perović-Ottstadt S, Kinzel O, Burnet M, Deuschle U, Kremoser C: Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists. Bioorg Med Chem Lett 2010;20:4911-4917.
114. Maloney PR, Parks DJ, Haffner CD, Fivush AM, Chandra G, Plunket KD, Creech KL, Moore LB, Wilson JG, Lewis MC, Jones SA, Willson TM: Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 2000;43:2971-2974.
115. Mehlmann JF, Crawley ML, Lundquist JT 4th, Unwalla RJ, Harnish DC, Evans MJ, Kim CY, Wrobel JE, Mahaney PE: Pyrrole[2,3-d] azepino compounds as agonists of the farnesoid X receptor (FXR). Bioorg Med Chem Lett 2009;19:5289-5292.
116. Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, Morelli A, Parks DJ, Willson TM: 6alpha-ethyl-cheno-deoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anti-cholestatic activity. J Med Chem 2002;45: 3569-3572.
117. Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Morelli A, Pruzanski M, Pellicciari R: Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther 2005;315:58-68.
118. 3 output. Hepatology 2011;54:1303-1312.
119. Fickert P, Fuchsbichler A, Moustafa T, Wagner M, Zollner G, Halilbasic E, Stöger U, Arrese M, Pizarro M, Solís N, Carrasco G, Caligiuri A, Sombetzki M, Reisinger E, Tsybrovskyy O, Zatloukal K, Denk H, Jaeschke H, Pinzani M, Trauner M: Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol 2009; 175: 2392-2405.
120. Hohenester S, Maillette de Buy Wenniger L, Jefferson DM, Oude Elferink RP, Beuers U: Biliary bicarbonate secretion constitutes a protective mechanism against bile acid-induced injury in man. Dig Dis 2011;29:62-65.
121. Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, Kowdley KV, Vincent C, Bodhenheimer HC Jr, Parés A, Trauner M, Marschall HU, Adorini L, Sciacca C, Beecher-Jones T, Castelloe E, Böhm O, Shapiro D: Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015;148: 751-761.e8.
122. Nevens F, Andreone P, Mazzella G, Strasser S, Bowlus C, Invernizzi P, Drenth J, Pockros P, Regula J, Hansen B, Hooshmand-Rad R, Sheeron S, Shapiro D: The first primary biliary cirrhosis (PBC) phase 3 trial in two decades - an international study of the FXR agonist obeticholic acid. J Hepatol 2014; 60:S525-S526.
123. Kowdley K, Nevens F, Andreone P, Luketic VA, Shah H, Pencek R, Marmon TK, Shapiro D: The first new trials for primary biliary cirrhosis in a decade: An international program evaluating the farnesoid X receptor agonist obeticholic acid. Gastroenterology 2015;148:S991-S992.
124. Karlsen TH, Franke A, Melum E, Kaser A, Hov JR, Balschun T, Lie BA, Bergquist A, Schramm C, Weismüller TJ, Gotthardt D, Rust C, Philipp EE, Fritz T, Henckaerts L, Weersma RK, Stokkers P, Ponsioen CY, Wijmenga C, Sterneck M, Nothnagel M, Hampe J, Teufel A, Runz H, Rosenstiel P, Stiehl A, Vermeire S, Beuers U, Manns MP, Schrumpf E, Boberg KM, Schreiber S: Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010;138:1102-1111.
125. Baghdasaryan A, Jha P, Müller M, Agostinelli L, Saccomanno S, Auer N, Deutschmann A, Zöhrer C, Auwerx J, Marzioni M, Fickert P, Trauner M: Protective role of membrane bile acid receptor TGR5 (GPBAR1) in DDC-induced sclerosing cholangitis in mice. J Hepatol 2014;60:S197-S198.
126. Keitel V, Reich M, Sommerfeld A, Kluge S, Kubitz R, Häussinger D: The bile acid receptor TGR5 promotes cholangiocyte proliferation through a cSRC-EGFR-ERK signalling pathway. J Hepatol 2013;58:S574-S575.
127. Luo J, Ko B, Elliott M, Zhou M, Lindhout DA, Phung V, To C, Learned RM, Tian H, DePaoli AM, Ling L: A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci Transl Med 2014;6:247ra100.
128. Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, Loo HL, Aung MO, Lim SG, Ullrich A: Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 2009;50:118-127.
129. Miethke AG, Zhang W, Simmons J, Taylor AE, Shi T, Shanmukhappa SK, Karns R, White S, Jegga AG, Lages CS, Nkinin S, Keller BT, Setchell KD: Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice. Hepatology 2015, Epub ahead of print.
130. Baghdasaryan A, Jha P, Müller M, Auer N, Deutschmann A, Zöhrer C, Påhlman I, Graffner P, Fickert P, Trauner M: Inhibition of intestinal bile acid absorption by ASBT inhibitor A4250 protects against bile acid-mediated cholestatic liver injury in mice. J Hepatol 2014;60:S57.
131. Day AP, Feher MD, Chopra R, Mayne PD: The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities. Metabolism 1993;42:839-842.
132. Matsumoto T, Miyazaki H, Nakahashi Y, Hirohara J, Seki T, Inoue K, Okazaki K: Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate. Hepatol Res 2004;30: 125-136.
133. Shoda J, Inada Y, Tsuji A, Kusama H, Ueda T, Ikegami T, Suzuki H, Sugiyama Y, Cohen DE, Tanaka N: Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4. J Lipid Res 2004;45: 1813-1825.
134. Kok T, Bloks VW, Wolters H, Havinga R, Jansen PL, Staels B, Kuipers F: Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem J 2003;369(pt 3):539-547.
135. Ghonem NS, Ananthanarayanan M, Soroka CJ, Boyer JL: Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. Hepatology 2014; 59:1030-1042.
136. Nakamuta M, Fujino T, Yada R, Yasutake K, Yoshimoto T, Harada N, Yada M, Higuchi N, Kato M, Kohjima M, Taketomi A, Maehara Y, Nishinakagawa T, Machida K, Matsunaga K, Nakashima M, Kotoh K, Enjoji M: Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway. Int J Clin Pharmacol Ther 2010; 48:22-28.
137. Post SM, Duez H, Gervois PP, Staels B, Kuipers F, Princen HM: Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated down-regulation of cholesterol 7alpha-hydroxy-lase and sterol 27-hydroxylase expression. Arterioscler Thromb Vasc Biol 2001;21: 1840-1845.
138. Honda A, Ikegami T, Nakamuta M, Miyazaki T, Iwamoto J, Hirayama T, Saito Y, Takikawa H, Imawari M, Matsuzaki Y: Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 2013; 57: 1931-1941.
139. Delerive P, Gervois P, Fruchart JC, Staels B: Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 2000;275:36703-36707.
140. Cuperus FJ, Halilbasic E, Trauner M: Fibrate treatment for primary biliary cirrhosis. Curr Opin Gastroenterol 2014;30:279-286.
141. Mizuno S, Hirano K, Tada M, Yamamoto K, Yashima Y, Yagioka H, Kawakubo K, Ito Y, Kogure H, Sasaki T, Arizumi T, Togawa O, Matsubara S, Nakai Y, Sasahira N, Tsujino T, Isayama H, Kawabe T, Omata M, Koike K: Bezafibrate for the treatment of primary sclerosing cholangitis. J Gastroenterol 2010; 45:758-762.
142. Hosonuma K, Sato K, Yamazaki Y, Yanagisawa M, Hashizume H, Horiguchi N, Kakizaki S, Kusano M, Yamada M: A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol 2015; 110:423-431.
143. Baghdasaryan A, Claudel T, Kosters A, Gumhold J, Silbert D, Thüringer A, Leski K, Fickert P, Karpen SJ, Trauner M: Curcumin improves sclerosing cholangitis in Mdr2-/-mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut 2010;59:521-530.
144. Beuers U, Trauner M, Jansen P, Poupon R: New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 2015;62(1 suppl):S25-S37.
145. Abramovitch S, Dahan-Bachar L, Sharvit E, Weisman Y, Ben Tov A, Brazowski E, Reif S: Vitamin D inhibits proliferation and pro-fibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut 2011;60: 1728-1737.
146. Hochrath K, Stokes CS, Geisel J, Pollheimer MJ, Fickert P, Dooley S, Lammert F: Vitamin D modulates biliary fibrosis in ABCB4-deficient mice. Hepatol Int 2014;8:443-452.
147. Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, Leblanc M, Coulter S, He M, Scott C, Lau SL, Atkins AR, Barish GD, Gunton JE, Liddle C, Downes M, Evans RM: A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 2013;153:601-613.
148. 3 prevents activation of hepatic stellate cells in vitro and ameliorates inflammatory liver damage but not fibrosis in the Abcb4(-/-) model. Biochem Biophys Res Commun 2015;459:227-233.
149. D'Aldebert E, Biyeyeme Bi Mve MJ, Mergey M, Wendum D, Firrincieli D, Coilly A, Fouassier L, Corpechot C, Poupon R, Housset C, Chignard N: Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology 2009;136:1435-1443.
150. Levin AA, Sturzenbecker LJ, Kazmer S, Bosakowski T, Huselton C, Allenby G, Speck J, Kratzeisen C, Rosenberger M, Lovey A, et al: 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha. Nature 1992;355:359-361.
151. Wang X, Allen C, Ballow M: Retinoic acid enhances the production of IL-10 while reducing the synthesis of IL-12 and TNF-alpha from LPS-stimulated monocytes/macrophages. J Clin Immunol 2007;27:193-200.
152. Rao J, Qian X, Wang P, Pu L, Zhai Y, Wang X, Zhang F, Lu L: All-trans retinoic acid preconditioning protects against liver ischemia/ reperfusion injury by inhibiting the nuclear factor kappa B signaling pathway. J Surg Res 2013;180:e99-e106.
153. Sharvit E, Abramovitch S, Reif S, Bruck R: Amplified inhibition of stellate cell activation pathways by PPAR-γ, RAR and RXR agonists. PLoS One 2013;8:e76541.
154. Hisamori S, Tabata C, Kadokawa Y, Okoshi K, Tabata R, Mori A, Nagayama S, Watanabe G, Kubo H, Sakai Y: All-trans-retinoic acid ameliorates carbon tetrachloride-induced liver fibrosis in mice through modulating cytokine production. Liver Int 2008; 28: 1217-1225.
155. Hellemans K, Verbuyst P, Quartier E, Schuit F, Rombouts K, Chandraratna RA, Schuppan D, Geerts A: Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids. Hepatology 2004;39:97-108.
156. Davis BH, Kramer RT, Davidson NO: Retinoic acid modulates rat Ito cell proliferation, collagen, and transforming growth factor beta production. J Clin Invest 1990;86:2062-2070.
157. He H, Mennone A, Boyer JL, Cai SY: Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology 2011;53:548-557.
158. Crestani M, Sadeghpour A, Stroup D, Galli G, Chiang JY: The opposing effects of retinoic acid and phorbol esters converge to a common response element in the promoter of the rat cholesterol 7 alpha-hydroxylase gene (CYP7A). Biochem Biophys Res Commun 1996;225:585-592.
159. Le Vee M, Jouan E, Stieger B, Fardel O: Differential regulation of drug transporter expression by all-trans retinoic acid in hepatoma HepaRG cells and human hepatocytes. Eur J Pharm Sci 2013;48:767-774.
160. Cai SY, Mennone A, Soroka CJ, Boyer JL: All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice. J Pharmacol Exp Ther 2014;349:94-98.
161. Rossen NG, Fuentes S, Boonstra K, D'Haens GR, Heilig HG, Zoetendal EG, de Vos WM, Ponsioen CY: The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. J Crohns Colitis 2015; 9:342-348.
162. Tabibian JH, O'Hara SP, Lindor KD: Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. Scand J Gastroenterol 2014;49:901-908.
163. Elfaki DA, Lindor KD: Antibiotics for the treatment of primary sclerosing cholangitis. Am J Ther 2011;18:261-265.
164. Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, Lindor KD: Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther 2013;37:604-612.
165. Silveira MG, Torok NJ, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor KD: Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol 2009;104: 83-88.
166. Färkkilä M, Karvonen AL, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P, Kärkkäinen P: Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004;40:1379-1386.
167. Tabibian JH, Gossard A, El-Youssef M, Eaton JE, Petz J, Jorgensen R, Enders FB, Tabibian A, Lindor KD: Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis. Am J Ther 2014, Epub ahead of print.
168. Mazagova M, Wang L, Anfora AT, Wissmueller M, Lesley SA, Miyamoto Y, Eckmann L, Dhungana S, Pathmasiri W, Sumner S, Westwater C, Brenner DA, Schnabl B: Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. FASEB J 2015; 29:1043-1055.
169. Tabibian JH, O'Hara SP, Trussoni CE, Tietz PS, Splinter PL, Mounajjed T, Hagey LR, LaRusso NF: Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology 2015, Epub ahead of print.
170. Vleggaar FP, Monkelbaan JF, van Erpecum KJ: Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur J Gastroenterol Hepatol 2008;20:688-692.
171. Shen J, Zuo ZX, Mao AP: Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis 2014; 20:21-35.
172. Bressler B, Marshall JK, Bernstein CN, Bit-ton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group: Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology 2015;148:1035-1058.e3.
173. Kitahara M, Takamine F, Imamura T, Benno Y: Clostridium hiranonis sp. nov., a human intestinal bacterium with bile acid 7alpha-dehydroxylating activity. Int J Syst Evol Microbiol 2001;51(pt 1):39-44.
174. Ridlon JM, Kang DJ, Hylemon PB: Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006;47:241-259.
175. Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A, Antonopoulos DA, Jabri B, Chang EB: Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/-mice. Nature 2012;487:104-108.
176. Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, Weinzierl M, Pape GR, Sauerbruch T, Paumgartner G: Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992;16:707-714.
177. Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L: Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994;20:57-64.
178. Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo primary sclerosing cholangitis-ursodeoxycholic acid study group. N Engl J Med 1997;336:691-695.
179. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW: A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-907.
180. Trauner M, Halilbasic E, Baghdasaryan A, Moustafa T, Krones E, Fickert P, Hofer H, Penner E: Primary sclerosing cholangitis: new approaches to diagnosis, surveillance andtreatment.DigDis2012;30(suppl1):39-47.
181. 3 prevents activation of hepatic stellate cells in vitro and ameliorates inflammatory liver damage but not fibrosis in the Abcb4(-/-) model. Biochem Biophys Res Commun 2015;459: 227-233.
182. Trauner M, Halilbasic E, Kazemi-Shirazi L, Kienbacher C, Staufer K, Traussnigg S, Hofer H: Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies. Dig Dis 2014;32:631-636.